王鴻偉 Hung-Wei Wang 主治醫師
王鴻偉醫師專長於胃腸道及肝膽疾病的相關診治，例如 : 腹痛、消化不良、便秘、腹瀉、胃食道逆流、巴瑞特氏食道、胃潰瘍、十二指腸潰瘍、大腸瘜肉、大腸激躁症、常見肝膽消化道疾病等。B型及C型肝炎、肝功能異常、肝硬化、肝癌診斷與治療。執行腹部超音波、胃鏡、內視鏡止血術、診斷性大腸鏡及大腸瘜肉切除術等內視鏡檢查。王醫師亦擅長於肝腫瘤細針穿刺檢查與肝腫瘤射頻消融術等相關治療。
分院掛號
學術機構典藏
論文
期刊論文
|
期刊論文／Journal Paper (作者群，論文題目，期刊名稱，出版年月，卷號(期別):頁次起迄) |
日期 | |
| 1 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)*、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、陳浤燿(Hung-Yao Chen)、張哲維(Che-Wei Chang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma，Journal of Gastrointestinal Oncology，2024 Sep，0(0):0-0 | 2024 . 09 |
| 2 | (Ying-Chun Shen)、(Tsung-Hao Liu)、(Alan Nicholas)、(Akihiko Soyama)、(Chang-Tsu Yuan)、(Tse-Ching Chen)、(Susumu Eguchi)、(Tomoharu Yoshizumi)、(Shinji Itoh)、(Noriaki Nakamura)、(Hisashi Kosaka)、(Masaki Kaibori)、(Takamichi Ishii)、(Etsuro Hatano)、(Chikara Ogawa)、(Atsushi Naganuma)、(Satoru Kakizaki)、(Chih-Hsien Cheng)、(Po-Ting Lin)、(Yung-Yeh Su)、(Chien-Huai Chuang)、(Li-Chun Lu)、(Chi-Jung Wu)、王鴻偉(Hung-Wei Wang)、(Kun-Ming Rau)、(Chih-Hung Hsu)、(Shi-Ming Lin)、(Yi-Hsiang Huang)、(Sairy Hernandez)、(Richard S. Finn)、(Masatoshi Kudo)、(Ann-Lii Cheng)*，Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab，JOURNAL OF CLINICAL ONCOLOGY，2024 Aug，0(0):1-11 | 2024 . 08 |
| 3 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳昇弘(Chen, Sheng-Hung)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus，American Journal of Cancer Research，2024 Apr，14(4):1914-1925 | 2024 . 04 |
| 4 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*，Liver stiffness and spleen stiffness predict distinct liver-related events after hepatitis C eradication with direct-acting antivirals，JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION，2024 Apr，S0929-6646(24):142-146 | 2024 . 04 |
| 5 | (Wei Teng)、王鴻偉(Hung-Wei Wang)、(Shi-Ming Lin)*，『Practice Guidelines』Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan，Liver Cancer，2024 Feb，():1-19 | 2024 . 02 |
| 6 | 張哲睿(CHANG CHE-JUI)、許偉帆(Hsu, Wei-Fan)*、鄭隆賓(Long-Bin Jeng)、賴學洲(Hsueh-Chou Lai)、許士超(Shih-Chao Hsu)、陳德鴻(Te-Hung Chen)、王鴻偉(Hung-Wei Wang)、彭成元(Peng, Cheng-Yuan)，Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion，Current Oncology，2023 Nov，30(12):10134-10141 | 2023 . 11 |
| 7 | 張哲維(Che-Wei Chang)、王鴻偉(Hung-Wei Wang)*、黃文信(Wen-Hsin Huang)、莊伯恒(Po-Heng Chuang)，Unusual upper gastrointestinal bleeding following radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma，Journal of Postgraduate Medicine，2023 Oct，69(4):237-238 | 2023 . 10 |
| 8 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、陳昇弘(Chen, Sheng-Hung)、朱家聲(Chia-Sheng Chu)、蘇文邦(Wen-Pang Su)、周仁偉(Jen-Wei Chou)、高榮達(Jung-Ta Kao)、陳浤燿(Hung-Yao Chen)、莊世杰(Shih-Chieh Chuang)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy，American Journal of Cancer Research，2023 Feb，13(2):654-668 | 2023 . 02 |
| 9 | 王鴻偉(Hung-Wei Wang)、陳啟益(Chi-Yi Chen)、賴學洲(Hsueh-Chou Lai)、胡琮輝(Tsung-Hui Hu)、蘇文邦(Wen-Pang Su)、盧勝男(Sheng-Nan Lu)、洪肇宏(Chao-Hung Hung)、莊伯恒(Po-Heng Chuang)、王景弘(Jing-Houng Wang)、陳建宏(Chien-Hung Chen)*、彭成元(Peng, Cheng-Yuan)*，Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy，American Journal of Cancer Research，2023 Feb，13(2):526 | 2023 . 02 |
| 10 | 許偉帆(Hsu, Wei-Fan)、許士超(Shih-Chao Hsu)、陳德鴻(Te-Hung Chen)、林建宏(Chien-Hung Lin)、林膺峻(Lin,Ying-Chun)、張裕煒(Yu-Wei Chang)、王鴻偉(Hung-Wei Wang)、廖裕民(Yu-Min Liao)、賴學洲(Hsueh-Chou Lai)、彭成元(Peng, Cheng-Yuan)*，Modified Albumin–Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy，Cancers，2022 Oct，14(20):5083 | 2022 . 10 |
| 11 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、謝宗霖(Tsung-Lin, Hsieh)、陳浤燿(Hung-Yao Chen)、彭成元(Peng, Cheng-Yuan)*，Combined Liver Stiffness and Α-fetoprotein further beyond the Sustained Virologic Response Visit as Predictors of Long-term Liver-related Events in Patients With Chronic Hepatitis C，Canadian Journal of Gastroenterology and Hepatology，2022 Jul，2022():5201443-5201443 | 2022 . 07 |
| 12 | 王鴻偉(Hung-Wei Wang)、(Pei-Chein Tsai)、(Chi-Yi Chen)、(Kuo-Chih Tseng)、賴學洲(Hsueh-Chou Lai)、(Hsing-Tao Kuo)、(Chao-Hung Hung)、(Shui-Yi Tung)、(Jing-Houng Wang)、(Jyh-Jou Chen)、(Pei-Lun Lee)、(Ron-Nan Chien)、(Chun-Yen Lin)、(Chi-Chieh Yang)、(Gin-Ho Lo)、(Chi-Ming Tai)、(Chih-Wen Lin)、(Jia-Horng Kao)、(Chun-Jen Liu)、(Chen-Hua Liu)、(Sheng-Lei Yan)、(Ming-Jong Bair)、(Wei-Wen Su)、(Cheng-Hsin Chu)、(Chih-Jen Chen)、(Ching-Chu Lo)、(Pin-Nan Cheng)、(Yen-Cheng Chiu)、(Chia-Chi Wang)、(Jin-Shiung Cheng)、(Wei-Lun Tsai)、(Han-Chieh Lin)、(Yi-Hsiang Huang)、(Jee-Fu Huang)、(Chia-Yen Dai)、(Wan-Long Chuang)、(Ming-Lung Yu)*、彭成元(Peng, Cheng-Yuan)*，Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study，American Journal of Cancer Research，2022 Jul，12(7):3164-3174 | 2022 . 07 |
| 13 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*，Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents，JOURNAL OF VIRAL HEPATITIS，2022 Jun，29():01-10 | 2022 . 06 |
| 14 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、蔡宗佑(Tsung-Yu Tsai)、陳浤燿(Hung-Yao Chen)、彭成元(Cheng-Yuan Peng)*，Liver and spleen stiffness surveillance through elastography during and after direct-acting antiviral therapy in patients with chronic hepatitis C，JOURNAL OF ULTRASOUND IN MEDICINE，2022 Apr，41(5):1169-1177 | 2022 . 04 |
| 15 | 許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳政國(Cheng-Kuo Chen)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、朱家聲(Chia-Sheng Chu)、周仁偉(Jen-Wei Chou)、陳昇弘(Chen, Sheng-Hung)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、彭成元(Peng, Cheng-Yuan)*，Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies，American Journal of Cancer Research，2021 Dec，11(12):6173-6187 | 2021 . 12 |
| 16 | 陳昇弘(Sheng-Hung Chen)、黃嘉琳(Chia-Lin Huang)、江宜平(I-Ping Chiang)、張孜菁(Tzu-Ching Chang)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、蔡宗佑(Tsung-Yu Tsai)、彭成元(Cheng-Yuan Peng)*，Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication，EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY，2021 Sep，33(9):1209-1217 | 2021 . 09 |
| 17 | 許偉帆(Hsu, Wei-Fan)、張凱智(CHANG, KAI-CHIH)、陳德鴻(Te-Hung Chen)、林建宏(Chien-Hung Lin)、林膺峻(Lin,Ying-Chun)、蔡明宏(Ming-Hung Tsai)、陳旆聿(Pei-Yu Chen)、王鴻偉(Hung-Wei Wang)、朱家聲(Chia-Sheng Chu)、彭成元(Cheng-Yuan Peng)*，Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma，MEDICINE，2021 Aug，100(33):e27000 | 2021 . 08 |
| 18 | 王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*，On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma，Cancers，2021 Jul，13(15):3758 | 2021 . 07 |
| 19 | 許偉帆(Hsu, Wei-Fan)、莊伯恒(Po-Heng Chuang)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、楊其穎(Chi-Ying Yang)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*，Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience，American Journal of Cancer Research，2020 Dec，10(12):4547-4560 | 2020 . 12 |
| 20 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)、(Tsung-Hui Hu)、蘇文邦(Wen-Pang Su)、(Sheng-Nan Lu)、林佳欣(Chia-Hsin Lin)、(Chao-Hung Hung)、莊伯恒(Po-Heng Chuang)、(Jing-Houng Wang)、(Mei-Hsuan Lee)、(Chien-Hung Chen)*、彭成元(Cheng-Yuan Peng)*，On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma，Cancers，2020 May，12(5):1177 | 2020 . 05 |
| 21 | 陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、蘇文邦(Wen-Pang Su)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*，Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication，CLINICAL INFECTIOUS DISEASES，2020 Jan，70(1):114-122 | 2020 . 01 |
| 22 | (Hsien-Chih Wu)、(Chia-Lin Huang,)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、蔡宗佑(Tsung-Yu Tsai)、陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*，Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis.，International Journal of Clinical and Experimental Pathology，2019 Dec，12(10):3819-3829 | 2019 . 12 |
| 23 | 許偉帆(Wei-Fan Hsu)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)*、林佳欣(Chia-Hsin Lin)、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*，Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents，BMC GASTROENTEROLOGY，2019 Apr，19(1):63 | 2019 . 04 |
| 24 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)、(Tsung-Hui Hu)、蘇文邦(Wen-Pang Su)、(Sheng-Nan Lu)、(Chia-Hsin Lin)、(Chao-Hung Hung)、莊伯恒(Po-Heng Chuang)、(Jing-Houng Wang)、(Mei-Hsuan Lee)、(Chien-Hung Chen)*、彭成元(Cheng-Yuan Peng)*，Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy，JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY，2018 Jul，(): | 2018 . 07 |
| 25 | 許偉帆(Wei-Fan Hsu)、陳春妃(Chuen-Fei Chen)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、王鴻偉(Hung-Wei Wang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*，Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy，LIVER INTERNATIONAL，2018 Apr，38(4):627-635 | 2018 . 04 |
| 26 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Lai, Hsueh-Chou)、江宜平(Chiang, I-Ping)、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Kao, Jung-Ta)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Chen, Ching-Hsiang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*，Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C，PLoS One，2018 Jan，13(1):e0190455-e0190455 | 2018 . 01 |
| 27 | 王鴻偉(Hung-Wei Wang)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、許偉帆(Wei-Fan Hsu)、黃冠棠，New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis，Scientific Reports，2017 Jun，7(1):3259 | 2017 . 06 |
| 28 | 王鴻偉(Hung-Wei Wang)、(Chia-Jung Kuo)、(Wey-Ran Lin)、(Chen-Ming Hsu)、(Yu-Pin Ho)、(Chun-Jung Lin)、(Ming-Yao Su)、(Cheng-Tang Chiu)*、(Kuang-Hua Chen)，The clinical characteristics and manifestations of cytomegalovirus esophagitis: Features of cytomegalovirus esophagitis，DISEASES OF THE ESOPHAGUS，2016 May，29(4):392-399 | 2016 . 05 |
| 29 | 王鴻偉(Hung-Wei Wang)、(Chia-Jung Kuo)、(Wey-Ran Lin)、(Chen-Ming Hsu)、(Yu-Pin Ho)、(Chun-Jung Lin)、(Ming-Yao Su)、(Cheng-Tang Chiu)*、(Kuang-Hua Chen)，Clinical Characteristics and Manifestation of Herpes Esophagitis: One Single-center Experience in Taiwan，MEDICINE，2016 Apr，95(14):e3187 | 2016 . 04 |
| 30 | 王鴻偉(Hung-Wei Wang)、(Chia-Jung Kuo)、(Wey-Ran Lin)、(Chen-Ming Hsu)、(Yu-Pin Ho)、(Chun-Jung Lin)、(Kuang-Hua Chen)、(Ming-Yao Su)、(Cheng-Tang Chiu)*，Barrett's esophagus and risk of esophageal adenocarcinoma: A retrospective analysis，Advances in Digestive Medicine，2015 Dec，2(4):135-140 | 2015 . 12 |
| 31 | (Chia-Jung Kuo)、(Kuang-Hui Yu)、(Lai-Chu See)、(Cheng-Tang Chiu)*、(Ming-Yao Su)、(Chen-Ming Hsu)、(Chang-Fu Kuo)、(Meng-Jiun Chiou)、(Jia-Rou Liu)、王鴻偉(Hung-Wei Wang)，The Trend of Inflammatory Bowel Diseases in Taiwan: A Population-Based Study，DIGESTIVE DISEASES AND SCIENCES，2015 Aug，60(8):2454-2462 | 2015 . 08 |
研討會論文
|
研討會論文／Conference Papers (發表主題或論文名稱，研討會名稱，演講地點，研討會期間，受邀演講題目) |
日期 | |
| 1 | Long-term dynamic changes of insulin resistance and lipid profiles in patients with hepatitis C viral eradication，2024TDDW台灣消化醫學週，高雄萬豪飯店，2024.10.04~2024.10.06， | 2024 . 10 |
| 2 | Risk Stratification of Liver-Related Events and Hepatocellular Carcinoma After Antiviral Treatment Using Baseline and Post-Treatment Liver Stiffness，Taiwan Digestive Disease Week (TDDW) 2024，Kaohsiung，2024.10.05~2024.10.06， | 2024 . 10 |
| 3 | Risk Stratification for Hepatocellular Carcinoma after Hepatitis C Cure using Metabolic and Fibrotic Biomarkers，APASL (The Asian Pacific Association for the Study of the Liver) STC on MAFLD 2024，Kaohsiung，2024.06.29~2024.06.30， | 2024 . 06 |
| 4 | Components of Cardiometabolic Criteria Predict Liver-Related Events in Patients Cured of Hepatitis C Virus，2024 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation，台中金典酒店，2024.05.18~2024.05.19， | 2024 . 05 |
| 5 | The Impact of Steatotic Liver Disease on Liver-Related Events in Patients Cured of Hepatitis C Virus，2024 The Asian Pacific Association for the Study of the Liver Annual Meeting，Kyoto International Conference Hall，2024.03.27~2024.03.31， | 2024 . 03 |
| 6 | The performance of the collagen proportionate area (CPA), Enhanced Liver Fibrosis (ELF) test, FIB-4, and Mac-2 binding protein glycosylation isomer (M2BPGi) in predicting the liver fibrosis stage in patients with chronic hepatitis C who received paired biopsies before and after antiviral therapy，2023 Taiwan Digestive Disease Week (2023 TDDW) 台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 7 | The Utility of Diabetes Mellitus Diagnosis and Post-Sustained Virologic Response Liver Stiffness Values in Predicting the Risk of Post-SVR Hepatocellular Carcinoma in Patients with Chronic Hepatitis C 慢性C型肝炎患者糖尿病診斷和持續病毒學反應後肝硬度值在預測持續病毒學反應後肝細胞癌風險中的意義和效用，Taiwan Digestive Disease Week 2023，National Sun Yat-sen University, Kaohsiung，2023.09.23~2023.09.24， | 2023 . 09 |
| 8 | Metabolic-Associated Fatty Liver Disease and Long-Term Risk of Hepatocellular Carcinoma in Treated Chronic Hepatitis B，2023 Taiwan Digestive Disease Week (2023 TDDW) 台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 9 | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT criteria，TDDW2023台灣消化醫學週，國立中山大學，2023.09.23~2023.09.24， | 2023 . 09 |
| 10 | Metabolic dysfunction but not echo liver steatosis increases the risk of liver related events in patients with cured hepatitis C，中華民國一一二年台灣消化系聯合學術演講年會，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 11 | The von Willebrand factor/platelet ratio as a surrogate biomarker of spleen stiffness measurement in patients with chronic hepatitis C after antiviral treatment，中華民國112 年消化系聯合學術演講年會 TDDW 2023，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 12 | B型肝炎表面抗原軌跡與抗原下降預測長期接受核苷酸類似物治療慢性B型肝炎患者療效，中華民國一一二年台灣消化系聯合學術演講年會，台北榮民總醫院，2023.03.25~2023.03.26， | 2023 . 03 |
| 13 | Trajectories of Serum Hepatitis B Surface Antigen Kinetics and Surface Antigen Decline Predict Treatment Outcomes in Patients with Chronic Hepatitis B Receiving Long-term Nucleos(t)ide Analogue Therapy，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 14 | Combined CRAFITY Score and A-fetoprotein Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Anti-programmed Death-1 Blockade–based Immunotherapy，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 15 | Metabolic Dysfunction but Not Ultrasonographic Hepatic Steatosis Increases the Risk of Liver-Related Events in Patients with Cured Hepatitis C，2023 The Asian Pacific Association for the Study of the Liver Annual Meeting，台北國際會議中心(TICC)，2023.02.15~2023.02.19， | 2023 . 02 |
| 16 | ，2022台灣肝癌醫學會國際教育研討會，台中榮民總醫院研究大樓第二及第三會議室，2022.12.04~2022.12.04，Maximize aHCC OS benefits with the well proven sequential therapy & CMUH RWE sharing | 2022 . 12 |
| 17 | ，OPTIMIZE TREATMENT EFFICACY OF HEPATOCELLULAR CARCINOMA FROM CLINICAL TRIALS TO TREATMENT PRACTICES IN VIETNAM & TAIWAN，National Cancer Hospital (K Hospital): base 2 and 3 (Hybrid)，2022.12.21~2022.12.21，Optimize treatment efficacy of uHCC: From clinical data to real world evidence from Taiwan | 2022 . 12 |
| 18 | Lenvatinib plus pembrolizumab for patients with unresectable hepatocellular carcinoma as 1st line systemic combination therapy: one single center real-world experience，2022 Taiwan Digestive Disease Week (2022 TDDW)，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 19 | Comparison of eight hepatocellular carcinoma risk prediction models in compensated cirrhotic patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy，2022 Taiwan Digestive Disease Week (2022 TDDW)，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 20 | Pretreatment and posttreatment spleen stiffness values as significant predictors of liver-related events in patients with chronic hepatitis C after direct-acting antiviral therapy治療前及治療後脾臟硬度測量可做為C型肝炎病患接受DAA治療後肝臟相關事件之顯著預測因子，2022 Taiwan Digestive Disease Week (2022 TDDW)，NTUH International Convention Center Taipei，2022.09.24~2022.09.25， | 2022 . 09 |
| 21 | Predictors of survival outcomes in patients with unresectable hepatocellular carcinoma treated with 1st line systemic therapy with lenvatinib: one single center real-world experience，2022 Taiwan Digestive Disease Week (2022 TDDW)，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 22 | Modified albumin–bilirubin model for stratifying survival in patients with hepatocellular carcinoma receiving anticancer therapy，2022TDDW台灣消化醫學週，台大國際會議中心，2022.09.24~2022.09.25， | 2022 . 09 |
| 23 | Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver related complications in patients with chronic hepatitis C receiving direct acting antiviral agents，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 24 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 25 | Modified cutoffs for ALBI grade for patients with early, intermediate, or advanced hepatocellular carcinoma，2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma，台大醫院國際會議中心，2022.06.23~2022.06.25， | 2022 . 06 |
| 26 | ，2022 APASL STC on HCC，NTUH International Convention Center in Taipei, Taiwan，2022.06.23~2022.06.25，NexSt Live Longer! Break 1L OS barrier with the well-proven sequential therapy for aHCC patients - CMUH NexSt RWD sharing | 2022 . 06 |
| 27 | ，臨床癌症治療與照護新知研討會(一)，台中金典酒店，2022.04.23~2022.04.23，化學治療引發肝功能異常之處置 | 2022 . 04 |
| 28 | Post-therapeutic nonalcoholic fatty liver disease fibrosis scores predicts liver-related complications in chronic hepatitis C patients receiving oral agents，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪飯店，2022.03.26~2022.03.27， | 2022 . 03 |
| 29 | Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and noninvasive fibrosis indices in patients with chronic hepatitis B: a pilot study，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪酒店，2022.03.26~2022.03.27， | 2022 . 03 |
| 30 | Clinical characteristics of patients receiving hepatitis B viral chemoprophylaxis after the implementation of expanded reimbursement criteria，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪飯店，2022.03.26~2022.03.27， | 2022 . 03 |
| 31 | ，中華民國一一一年台灣消化系聯合學術演講年會，高雄萬豪酒店，2022.03.26~2022.03.27，Integrating Real-World Evidence of Immunotherapy into Daily Practice for Advanced HCC | 2022 . 03 |
| 32 | Maximize aHCC Patients Survival Benefits with the Well-Proven Sequential Therapy - CMUH Real World Data Sharing，2021 台灣肝癌醫學會教育研討會(實體會議)，臺中市林酒店，2021.11.5 ~2021.12.5 ， | 2021 . 11 |
| 33 | Utility of long-term posttreatment liver stiffness follow-ups in prediction of liver-related events in patients with chronic hepatitis C – Combined α-fetoprotein and liver stiffness far beyond SVR to predict longer-term liver-related events in CHC – a rea，2021 Taiwan Digestive Disease Week，Online Conference (during COVID-19 pandemic)，2021.09.24~2021.09.26， | 2021 . 09 |
| 34 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma，2021TDDW台灣消化醫學週，台大醫院國際會議中心，2021.09.25~2021.09.26， | 2021 . 09 |
| 35 | Stratification of hepatocellular carcinoma risk through the combination of FIB-4 and ALBI-based prediction model in compensated cirrhotic patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy，TDDW2021 台灣消化醫學週，線上會議(virtual meeting)，2021.09.24~2021.09.26， | 2021 . 09 |
| 36 | Risk stratification of hepatocellular carcinoma incidence by FIB-4-based prediction model in patients with chronic hepatitis c receiving anti-viral therapy: a nationwide real-world Taiwanese cohort (T-COACH)，TDDW2021 台灣消化醫學週，線上會議(virtual meeting)，2021.09.24~2021.09.26， | 2021 . 09 |
| 37 | Comparison of overall survival between patients with unresectable hepatocellular carcinoma receiving sorafenib-regorafenib sequential therapy and those failing sorafenib therapy: single medical center experience，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 38 | ALBI grade: a predictor of treatment response and outcome for patients with unresectable hepatocellular carcinoma receiving sorafenib-regorafenib sequential therapy，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 39 | Nivolumab therapy with and without combination of tyrosine kinase inhibitor for patients with unresectable hepatocellular carcinoma，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 40 | Longitudinal changes in acoustic radiation force impulse (ARFI) values in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 41 | Comparison of ten liver functional reserve models for overall survival in patients with intermediate-stage hepatocellular carcinoma and different stratification，中華民國一一O年台灣消化系聯合學術演講年會，中國醫藥大學英才校區，2021.03.27~2021.03.28， | 2021 . 03 |
| 42 | An unusual case of bowel habit change caused by rectal endometriosis mimicking colon cancer，International Digestive Disease Forum，視訊線上會議，2020.11.22~2020.11.23， | 2020 . 11 |
| 43 | ，強化早期臨床試驗能量計畫，張榮發國際會議中心，2020.11.19~2020.11.19，早期臨床試驗人才海外培訓經驗分享座談會 | 2020 . 11 |
| 44 | 年輕女性臨床表現疑似大腸癌經大腸鏡診斷為直腸內子宮內膜異位，109年內科醫學會年會，台大醫院國際會議中心三樓走廊(台北市徐州路2號)，2020.11.28~2020.11.29， | 2020 . 11 |
| 45 | ，Application of Sonazoid-enhanced US: Workshop and Consensus Meeting (II)，張榮發基金會國際會議中心，2020.11.21~2020.11.21，超音波對比劑應用經驗分享Application of Sonazoid enhanced US :Experience sharing | 2020 . 11 |
| 46 | Longitudinal Analyses of the Biphasic Kinetics in Liver and Spleen Stiffness Values in Hepatitis C Virus-Infected Patients on and off Direct-Acting Antiviral Therapies 分析接受Direct-Acting Antivirals治療之C型肝炎病患治療中及治療後肝臟及脾臟硬度跨越時間之雙相變化，Taiwan Digestive Disease Week (TDDW) 2020，National Taiwan University Hospital International Convention Center，2020.09.25~2020.09.27， | 2020 . 09 |
| 47 | A combination of the one-year changes in FIB-4 and modified FIB-4 values helps to identify cirrhotic HBV patients with the minimal annual risk of hepatocellular carcinoma beyond year 5 of entecavir therapy，台灣消化醫學週 TDDW 2020，台大國際會議中心，2020.09.26~2020.09.27， | 2020 . 09 |
| 48 | Post-treatment liver stiffness measurement using acoustic radiation force impulse predicts incident hepatocellular carcinoma in chronic hepatitis C patients with advanced liver fibrosis，2020台灣消化系醫學週，台大醫院國際會議中心，2020.09.26~2020.09.27， | 2020 . 09 |
| 49 | Increased annual risk of hepatocellular carcinoma persists up to 7 years of entecavir therapy in chronic hepatitis B patients with baseline cirrhosis and higher modified FIB-4 value，中華民國109年消化系聯合學術演講年會，國防醫學中心，2020.07.11~2020.07.12， | 2020 . 07 |
| 50 | Risk stratification of hepatocellular carcinoma occurrence and overall mortality by albumin-bilirubin (ALBI) grade in Asian cirrhotic patients with chronic hepatitis B on entecavir therapy，中華民國109年消化系聯合學術演講年會，國防醫學中心，2020.07.11~2020.07.12， | 2020 . 07 |
| 51 | On-treatment changes in FIB-4 and one-year FIB-4 values helps identify chronic hepatitis B patients receiving entecavir therapy with the lowest risk of hepatocellular carcinoma，2019 TDDW 台灣消化醫學週，高雄展覽館，2019.09.28~2019.09.29， | 2019 . 09 |
| 52 | Stratification of hepatocellular carcinoma risk through the on-treatment changes in APRI and FIB-4 values in Asian patients with chronic hepatitis B receiving entecavir therapy，中華民國一零八年台灣消化系聯合學術演講年會，國防醫學中心，2019.03.30~2019.03.31， | 2019 . 03 |
| 53 | ，108年度乳癌治療新知學術研討會(二)，台中亞緻大飯店(Hotel ONE)，2019.03.09~2019.03.09，化學治療引發肝功能異常之處置 | 2019 . 03 |
| 54 | Albumin-bilirubin (ALBI) grade does not predict or stratify the risk of hepatocellular carcinoma in Asian patients with chronic hepatitis B treated with entecavir，中華民國一零八年台灣消化系聯合學術演講年會，國防醫學中心，2019.03.30~2019.03.31， | 2019 . 03 |
| 55 | Direct-acting antiviral agents in the treatment of chronic hepatitis C experience from China Medical University Hospital，中區消化系同好會 (107/11)，裕元花園酒店4F東側包廂，2018.11.01~2018.11.01， | 2018 . 11 |
| 56 | Abnormal on-treatment AST is associated with a higher risk of HCC occurrence in patients with CHB under entecavir therapy，2018台灣消化系醫學週，臺大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 57 | Distinct diagnostic performance for noninvasive fibrosis indices in patients with chronic hepatitis C before and after antiviral therapy，2018台灣消化系醫學週，臺大醫院國際會議中心，2018.09.29~2018.09.30， | 2018 . 09 |
| 58 | Fusion image guided percutaneous focal therapy to liver malignancy did not increase the complication rate than without fusion，APASL Single Topic Conference on HCC，PACIFICO Yokohama Conference Center，2018.05.11~2018.05.13， | 2018 . 05 |
| 59 | Modified Fibrosis-4 index stratifies the risk of hepatocellular carcinoma in Asian patients with chronic hepatitis B treated with entecavi，中華民國一O七年台灣消化系聯合學術演講年會，台大醫院國際會議中心，2018.03.24~2018.03.25， | 2018 . 03 |
| 60 | 非侵入性肝臟纖維化指標和聲幅射立脈波(ARFI)超音波在原發性膽汁性肝硬化患者之初步研究，中華民國一O七年台灣消化系聯合學術演講年會，台大醫院國際會議中心，2018.03.24~2018.03.25， | 2018 . 03 |
| 61 | Changes of Renal Function During and After HCV Therapy with Peginterferon and Ribavirin and Its Influencing Factors，2017 台灣消化醫學週，台大醫院國際會議中心，2017.09.29~2017.10.01， | 2017 . 09 |
| 62 | The combination of noninvasive assessment for liver fibrosis in chronic viral hepatitis by using modified FIB-4 and acoustic radiation force impulse: a single-center experience，2017 台灣消化醫學週，台大醫院國際會議中心，2017.09.29~2017.10.01， | 2017 . 09 |
| 63 | Comparison of non-invasive indices for the prediction of liver fibrosis in chronic viral hepatitis，中華民國一○六年消化系聯合學術演講年會，臺中榮民總醫院，2017.03.18~2017.03.19， | 2017 . 03 |
| 64 | 使用貝樂克治療慢性B型肝炎之亞洲患者其肝細胞癌的風險預測模型，中華民國一○六年消化系聯合學術演講年會，臺中榮民總醫院，2017.03.18~2017.03.19， | 2017 . 03 |
| 65 | Comparison of non-invasive indices for the prediction of liver cirrhosis in chronic viral hepatitis，2016 TDDW 台灣消化醫學週，台北，2016.10.01~2016.10.02， | 2016 . 10 |
專書
暫無資料研究計畫
|
研究計畫／Research Grant (研究類型，研究計畫代號，主持人，補助或委託單位名稱，計畫名稱，計畫期間) |
日期 | |
| 1 | 個別型，DMR-HHC-109-3，賴學洲(Hsueh-Chou Lai)、王鴻偉(Hung-Wei Wang)、朱家聲(Chia-Sheng Chu)，附醫院內計畫，中藥XSLJZ治療晚期肝癌多重激酶抑制劑安全及有效性評估: 隨機、雙盲、臨床試驗，2020.5.1~2021.4.30 | 2020 . 05 |
| 2 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Chen, Sheng-Hung)、王鴻偉(Hung-Wei Wang)、許偉帆(Hsu, Wei-Fan)，，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2020.1.1~2020.12.31 | 2020 . 01 |
| 3 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Sheng-Hung Chen)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2019.1.1~2019.12.31 | 2019 . 01 |
| 4 | 臨床試驗與研究計畫，CMUH106-REC3-134，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、陳昇弘(Sheng-Hung Chen)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，以Elbasvir/Grazoprevir治療未曾接受治療以及曾接受治療的慢性C型肝炎病毒基因亞型1b感染之血液透析患者，2018.1.1~2018.12.31 | 2018 . 01 |
| 5 | 臨床試驗與研究計畫，CMUH106-REC1-157，賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、陳昇弘(Sheng-Hung Chen)、陳浤燿(Hung-Yao Chen)、莊伯恒(Po-Heng Chuang)，附醫廠商計畫，探討8週或12週elbasvir合併grazoprevir對於C型肝炎病毒基因型1b無治療經驗且有輕微肝纖維化患者之療效差異:開放隨機分配性試驗(EGALITE)，2018.1.1~2018.12.31 | 2018 . 01 |
| 6 | 臨床試驗與研究計畫，CMUH106-REC2-108，賴學洲(Lai, Hsueh-Chou)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳景祥、陳昇弘(Chen, Sheng-Hung)、許偉凡、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，評估LJN452使用於非酒精性脂肪性肝炎(NASH)病患之安全性、耐受性與療效的一項隨機分配、雙盲、安慰劑對照、兩階段、適應性設計、多中心的12週試驗，2017.1.1~2017.12.31 | 2017 . 01 |
| 7 | 臨床試驗與研究計畫，CMUH105-REC1-141，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，評估單一遞增劑量與多重劑量GSK3389404使用於慢性B型肝炎受試者之安全性、耐受性、藥動學與藥效學的一項雙盲、安慰劑對照試驗，2017.1.1~2017.12.31 | 2017 . 01 |
| 8 | 臨床試驗與研究計畫，CMUH106-REC2-070，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，一項第 2 期、多中心、開放標示試驗，在患有基因型1、4、5、6 慢性C型肝炎感染且接受透析治療的末期腎病受試者中，評估Ledipasvir/Sofosbuvir 的療效及安全性，2017.1.1~2017.12.31 | 2017 . 01 |
| 9 | 臨床試驗與研究計畫，CMUH106-REC3-101，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，針對感染慢性C型肝炎病毒(HCV)基因型1、2、4、5 或6 型且具有代償性肝硬化而未接受過治療的成人評估Glecaprevir (GLE)/Pibrentasvir (PIB)的療效與安全性的一項單組、開放性試驗，2017.1.1~2017.12.31 | 2017 . 01 |
| 10 | 臨床試驗與研究計畫，CMUH106-REC3-054，彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥、陳昇弘(Chen, Sheng-Hung)、許偉帆(Wei-Fan Hsu)，附醫廠商計畫，針對先前接受全身性治療的晚期肝細胞癌亞洲受試者，比較Pembrolizumab併用最佳支持性照護相對於安慰劑併用最佳支持性照護，作為第二線療法的一項隨機分配、雙盲第三期試驗(KEYNOTE-394)，2017.1.1~2017.12.31 | 2017 . 01 |
| 11 | 臨床試驗與研究計畫，CMUH105-REC1-102，彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥、陳昇弘(Chen, Sheng-Hung)，附醫廠商計畫，針對先前接受全身性治療的晚期肝細胞癌受試者，比較Pembrolizumab (MK-3475)與最佳支持性照護作為第二線療法的一項第三期試驗(KEYNOTE-240)，2017.1.1~2017.12.31 | 2017 . 01 |
| 12 | 臨床試驗與研究計畫，CMUH106-REC1-069，賴學洲(Lai, Hsueh-Chou)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、許偉凡、王鴻偉(Hung-Wei Wang)，附醫廠商計畫，一項第三期、隨機分配、雙盲、安慰劑對照試驗，在患有非酒精性脂肪肝(NASH)和橋接(F3)纖維化的受試者中，評估 Selonsertib 的安全性和療效，2017.1.1~2017.12.31 | 2017 . 01 |
| 13 | 臨床試驗與研究計畫，CMUH106-REC2-016，賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、陳昇弘(Chen, Sheng-Hung)、陳景祥，附醫廠商計畫，探討12週daclatasvir/asunaprevir合併ribavirin對C型肝炎病毒基因型1b無NS5A病毒突變株患者治療療效與安全性研究，2017.1.1~2017.12.31 | 2017 . 01 |
| 14 | 臨床試驗與研究計畫，CMUH105-REC1-102，彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥(Ching-Hsiang Chen)、陳昇弘(Sheng-Hung Chen)，附醫廠商計畫，針對先前接受全身性治療的晚期肝細胞癌受試者，比較Pembrolizumab (MK-3475)與最佳支持性照護作為第二線療法的一項第三期試驗(KEYNOTE-240)，2016.1.1~2016.12.31 | 2016 . 01 |
專利技術
暫無資料獲獎事蹟
|
獲獎／Award (獲獎名稱，給獎單位，獲獎日期) |
日期 | |
| 1 | Outstanding Poster Award，台灣肝癌醫學會，2024.5.18 | 2024 . 05 |
| 2 | 2022 APASL-TOP 100 Outstanding Abstract，Asian Pacific Association for the Study of the Liver，2022.6.25 | 2022 . 06 |
